Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2004 1
2006 1
2007 1
2008 3
2009 4
2010 2
2011 6
2012 5
2013 13
2014 15
2015 16
2016 13
2017 24
2018 15
2019 14
2020 13
2021 10
2022 9
2023 11
2024 12
2025 13
2026 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

183 results

Results by year

Filters applied: . Clear all
Page 1
Presenting Symptoms in Men and Women Diagnosed With Myocardial Infarction Using Sex-Specific Criteria.
Ferry AV, Anand A, Strachan FE, Mooney L, Stewart SD, Marshall L, Chapman AR, Lee KK, Jones S, Orme K, Shah ASV, Mills NL. Ferry AV, et al. J Am Heart Assoc. 2019 Sep 3;8(17):e012307. doi: 10.1161/JAHA.119.012307. Epub 2019 Aug 20. J Am Heart Assoc. 2019. PMID: 31431112 Free PMC article. Clinical Trial.
Diagnosis of myocardial infarction was adjudicated using a high-sensitivity cardiac troponin I assay with sex-specific thresholds (>16 ng/L women, >34 ng/L men). ...Type 1 myocardial infarction was diagnosed in 16% (184/1185) of men and 12% (90/7 …
Diagnosis of myocardial infarction was adjudicated using a high-sensitivity cardiac troponin I assay with sex-sp …
Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
Henriksen PA, Hall P, MacPherson IR, Joshi SS, Singh T, Maclean M, Lewis S, Rodriguez A, Fletcher A, Everett RJ, Stavert H, Broom A, Eddie L, Primrose L, McVicars H, McKay P, Borley A, Rowntree C, Lord S, Collins G, Radford J, Guppy A, Williams MC, Japp A, Payne JR, Newby DE, Mills NL, Oikonomidou O, Lang NN. Henriksen PA, et al. Circulation. 2023 Nov 21;148(21):1680-1690. doi: 10.1161/CIRCULATIONAHA.123.064274. Epub 2023 Sep 25. Circulation. 2023. PMID: 37746692 Free PMC article. Clinical Trial.
Patients at high risk of cardiotoxicity (cardiac troponin I concentrations in the upper tertile during chemotherapy) were randomized to standard care plus cardioprotection (combination carvedilol and candesartan therapy) or standard care alone. ...In low-risk nonran …
Patients at high risk of cardiotoxicity (cardiac troponin I concentrations in the upper tertile during chemotherapy) were rand …
Effectiveness of Point-of-Care High-Sensitivity Troponin Testing in the Emergency Department: A Randomized Controlled Trial.
Thulin VIL, Jordalen SMF, Myrmel GMS, Lekven OC, Krishnapillai J, Steiro OT, Body R, Collinson P, Apple FS, Cullen L, Norekvål TM, Wisløff T, Vikenes K, Bjørneklett RO, Omland T, Aakre KM. Thulin VIL, et al. Ann Emerg Med. 2025 Aug;86(2):124-135. doi: 10.1016/j.annemergmed.2025.03.005. Epub 2025 Apr 9. Ann Emerg Med. 2025. PMID: 40202469 Free article. Clinical Trial.
STUDY OBJECTIVE: To compare the effectiveness of high-sensitivity cardiac troponin (hs-cTn) point-of-care testing to central laboratory hs-cTn measurements when investigating patients presenting to the emergency department (ED) with symptoms of acute coronary syndro …
STUDY OBJECTIVE: To compare the effectiveness of high-sensitivity cardiac troponin (hs-cTn) point-of-care testing to central l …
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4.
Masri A, Sherrid MV, Abraham TP, Choudhury L, Garcia-Pavia P, Kramer CM, Barriales-Villa R, Owens AT, Rader F, Nagueh SF, Olivotto I, Saberi S, Tower-Rader A, Wong TC, Coats CJ, Watkins H, Fifer MA, Solomon SD, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Meng L, Sohn RL, Wohltman A, Maron MS; REDWOOD-HCM Investigators. Masri A, et al. J Card Fail. 2024 Nov;30(11):1439-1448. doi: 10.1016/j.cardfail.2024.02.020. Epub 2024 Mar 15. J Card Fail. 2024. PMID: 38493832 Free article. Clinical Trial.
Symptom relief was paralleled by reductions in NT-proBNP levels (56%; P < 0.001) and high-sensitivity cardiac troponin I (22%; P < 0.005). Modest reductions in LVEF (mean SD) of -5.4% 10 to 64.6% 9.1 were observed. ...

Symptom relief was paralleled by reductions in NT-proBNP levels (56%; P < 0.001) and high-sensitivity cardiac troponin

…
Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: A 36-week analysis from FOREST-HCM.
Masri A, Barriales-Villa R, Elliott P, Nassif ME, Oreziak A, Owens AT, Tower-Rader A, Heitner SB, Kupfer S, Malik FI, Melloni C, Meng L, Wei J, Saberi S;  on behalf of the FOREST‐HCM Investigators. Masri A, et al. Eur J Heart Fail. 2024 Sep;26(9):1993-1998. doi: 10.1002/ejhf.3372. Epub 2024 Jul 18. Eur J Heart Fail. 2024. PMID: 39023326 Free article. Clinical Trial.

Median (interquartile range) levels of N-terminal pro-B-type natriuretic peptide were significantly improved from baseline (-665.5 pg/ml [-1244.0, -232.0]; p < 0.0001), while high-sensitivity cardiac troponin I was unchanged (-2.7 ng/L [-11.3, 1.6];

…
Median (interquartile range) levels of N-terminal pro-B-type natriuretic peptide were significantly improved from baseline (-665.5 pg/ml [-1 …
Cardiac Effects of Dapagliflozin in People with Chronic Kidney Disease.
Bartholdy KV, Johansen ND, Skaarup KG, Modin D, Landler N, Langhoff AF, Ottosen CI, Espersen C, Dons M, Borchsenius JIM, Davodian LW, Lassen MH, Davidovski FS, Jensen AMR, Sengeløv M, Christensen J, Schou M, Feldt-Rasmussen B, Jensen J, Bressendorff I, Persson F, Rossing P, Køber L, Zannad F, Vaduganathan M, Solomon S, Haynes R, Hansen D, Biering-Sørensen T. Bartholdy KV, et al. NEJM Evid. 2025 Nov;4(11):EVIDoa2500158. doi: 10.1056/EVIDoa2500158. Epub 2025 Oct 28. NEJM Evid. 2025. PMID: 41147829 Clinical Trial.
Secondary end points included changes in systolic and diastolic function, high-sensitivity troponin I, pro-B-type natriuretic peptides, hemoglobin, the urine albumin-creatinine ratio, and creatinine. ...
Secondary end points included changes in systolic and diastolic function, high-sensitivity troponin I, pro-B-typ …
Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial.
Bonatto MG, Avila MS, Ayub Ferreira SM, Lechinewski LD, Torres RA, Costa AN, Costa NRAD, Coiradas AO, Mialski TBR, Maiolino J, Ota TT, Contin L, Mosko LA, Bittencourt MS, Cauduro S, Zytynski Moura LA, Bocchi EA. Bonatto MG, et al. Circulation. 2025 Dec 23;152(25):1742-1755. doi: 10.1161/CIRCULATIONAHA.125.073322. Epub 2025 Nov 13. Circulation. 2025. PMID: 41230611 Clinical Trial.
This study evaluated the efficacy of sacubitril-valsartan in reducing cardiotoxicity in patients with increased cardiac troponin I concentrations during anthracycline chemotherapy. METHODS: This randomized, double-blind, placebo-controlled trial enrolled 114 patient …
This study evaluated the efficacy of sacubitril-valsartan in reducing cardiotoxicity in patients with increased cardiac troponin I …
Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines.
Thavendiranathan P, Houbois C, Marwick TH, Kei T, Saha S, Runeckles K, Huang F, Shalmon T, Thorpe KE, Pezo RC, Prica A, Maze D, Abdel-Qadir H, Connelly KA, Chan J, Billia F, Power C, Hanneman K, Wintersperger BJ, Brezden-Masley C, Amir E. Thavendiranathan P, et al. Eur Heart J Cardiovasc Pharmacother. 2023 Sep 20;9(6):515-525. doi: 10.1093/ehjcvp/pvad031. Eur Heart J Cardiovasc Pharmacother. 2023. PMID: 37120736 Free PMC article. Clinical Trial.
Secondary endpoints included left ventricular (LV) volumes, CTRCD, CMR tissue characterization, high sensitivity troponin I (hsTnI), and B-type natriuretic peptide (BNP). RESULTS: We randomized 112 patients (56.9 13.6 years, 87 female, and 73 with br …
Secondary endpoints included left ventricular (LV) volumes, CTRCD, CMR tissue characterization, high sensitivity troponin …
Cardiac Myosin Inhibition in Heart Failure With Normal and Supranormal Ejection Fraction: Primary Results of the EMBARK-HFpEF Trial.
Shah SJ, Rigolli M, Javidialsaadi A, Patel RB, Khadra S, Goyal P, Little S, Wever-Pinzon O, Owens AT, Skali H, Arora P, Solomon SD. Shah SJ, et al. JAMA Cardiol. 2025 Feb 1;10(2):170-175. doi: 10.1001/jamacardio.2024.3810. JAMA Cardiol. 2025. PMID: 39347697 Free PMC article. Clinical Trial.
MAIN OUTCOMES AND MEASURES: Primary efficacy end points (measured as the change from baseline to week 26) included NTproBNP and high-sensitivity troponin T (hsTnT); additional efficacy end points included changes in high-sensitivity troponin …
MAIN OUTCOMES AND MEASURES: Primary efficacy end points (measured as the change from baseline to week 26) included NTproBNP and high- …
Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy: Insights From the ODYSSEY-HCM Trial.
Desai MY, Olivotto I, Abraham T, Nissen SE, Garcia-Pavia P, Lopes RD, Elliott PM, Fernandes F, de Barros Correia E, Barriales-Villa R, Zorio E, Arad M, Shin SH, Verheyen N, Meder B, Azevedo O, Kitaoka H, Wolski K, Wang Q, Suryawanshi B, Wang Z, Florea V, Aronson R, Owens AT; ODYSSEY-HCM Investigators. Desai MY, et al. J Am Coll Cardiol. 2025 Dec 16;86(24):2418-2433. doi: 10.1016/j.jacc.2025.08.017. Epub 2025 Aug 27. J Am Coll Cardiol. 2025. PMID: 40864018 Clinical Trial.
OBJECTIVES: The current exploratory analysis from the ODYSSEY-HCM trial reports the associations between: 1) baseline biomarkers (N-terminal pro-B-type natriuretic peptide [NT-proBNP] and high-sensitivity cardiac troponin I [cTnI]) with clinical, exerc …
OBJECTIVES: The current exploratory analysis from the ODYSSEY-HCM trial reports the associations between: 1) baseline biomarkers (N-terminal …
183 results